These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33497547)

  • 1. Bupropion and Naltrexone in Methamphetamine Use Disorder.
    Trivedi MH; Walker R; Ling W; Dela Cruz A; Sharma G; Carmody T; Ghitza UE; Wahle A; Kim M; Shores-Wilson K; Sparenborg S; Coffin P; Schmitz J; Wiest K; Bart G; Sonne SC; Wakhlu S; Rush AJ; Nunes EV; Shoptaw S
    N Engl J Med; 2021 Jan; 384(2):140-153. PubMed ID: 33497547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder.
    Mooney LJ; Hillhouse MP; Thomas C; Ang A; Sharma G; Terry G; Chang L; Walker R; Trivedi M; Croteau D; Sparenborg S; Ling W
    J Addict Med; 2016; 10(4):236-43. PubMed ID: 27379819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
    Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial.
    Coffin PO; Santos GM; Hern J; Vittinghoff E; Santos D; Matheson T; Colfax G; Batki SL
    Addiction; 2018 Feb; 113(2):268-278. PubMed ID: 28734107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sexual orientation differences among men in a randomized clinical trial of extended-release naltrexone and bupropion for methamphetamine use disorder.
    Kidd JD; Smiley SL; Coffin PO; Carmody TJ; Levin FR; Nunes EV; Shoptaw SJ; Trivedi MH
    Drug Alcohol Depend; 2023 Sep; 250():110899. PubMed ID: 37478502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication Adherence Monitoring Using Smartphone Video Dosing in an Open-label Pilot Study of Monthly Naltrexone Plus Once-daily Bupropion for Methamphetamine Use Disorder: Feasibility and Acceptability.
    Walker R; Hillhouse M; Perrochet B; Sparenborg S; Mooney L; Ling W
    J Addict Med; 2019; 13(5):372-378. PubMed ID: 30724759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A gender-based secondary analysis of the ADAPT-2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial.
    Levander XA; Carmody T; Cook RR; Potter JS; Trivedi MH; Korthuis PT; Shoptaw S
    Addiction; 2023 Jul; 118(7):1320-1328. PubMed ID: 36864016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial.
    Li MJ; Chau B; Belin T; Carmody T; Jha MK; Marino EN; Trivedi M; Shoptaw SJ
    Addiction; 2024 Jun; ():. PubMed ID: 38856086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
    Wadden TA; Foreyt JP; Foster GD; Hill JO; Klein S; O'Neil PM; Perri MG; Pi-Sunyer FX; Rock CL; Erickson JS; Maier HN; Kim DD; Dunayevich E
    Obesity (Silver Spring); 2011 Jan; 19(1):110-20. PubMed ID: 20559296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial.
    Anderson AL; Li SH; Markova D; Holmes TH; Chiang N; Kahn R; Campbell J; Dickerson DL; Galloway GP; Haning W; Roache JD; Stock C; Elkashef AM
    Drug Alcohol Depend; 2015 May; 150():170-4. PubMed ID: 25818061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
    Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
    Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naltrexone plus bupropion reduces cigarette smoking in individuals with methamphetamine use disorder: A secondary analysis from the CTN ADAPT-2 trial.
    Schmitz JM; Stotts AL; Yoon JH; Northrup TF; Villarreal YR; Yammine L; Weaver MF; Carmody T; Shoptaw S; Trivedi MH
    J Subst Use Addict Treat; 2023 Aug; 151():208987. PubMed ID: 36822269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial.
    Krupitsky E; Blokhina E; Zvartau E; Verbitskaya E; Lioznov D; Yaroslavtseva T; Palatkin V; Vetrova M; Bushara N; Burakov A; Masalov D; Mamontova O; Langleben D; Poole S; Gross R; Woody G
    Lancet HIV; 2019 Apr; 6(4):e221-e229. PubMed ID: 30880163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial.
    Collins SE; Duncan MH; Saxon AJ; Taylor EM; Mayberry N; Merrill JO; Hoffmann GE; Clifasefi SL; Ries RK
    Lancet Psychiatry; 2021 Apr; 8(4):287-300. PubMed ID: 33713622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of prospectively determined A118G polymorphism on treatment response to injectable naltrexone among methamphetamine-dependent patients: an open-label, pilot study.
    Pal R; Mendelson JE; Flower K; Garrison K; Yount G; Coyle JR; Galloway GP
    J Addict Med; 2015; 9(2):130-5. PubMed ID: 25622123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
    Nissen SE; Wolski KE; Prcela L; Wadden T; Buse JB; Bakris G; Perez A; Smith SR
    JAMA; 2016 Mar; 315(10):990-1004. PubMed ID: 26954408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bupropion for the treatment of methamphetamine dependence.
    Elkashef AM; Rawson RA; Anderson AL; Li SH; Holmes T; Smith EV; Chiang N; Kahn R; Vocci F; Ling W; Pearce VJ; McCann M; Campbell J; Gorodetzky C; Haning W; Carlton B; Mawhinney J; Weis D
    Neuropsychopharmacology; 2008 Apr; 33(5):1162-70. PubMed ID: 17581531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Separate and Combined Effects of Naltrexone and Extended-Release Alprazolam on the Reinforcing, Subject-Rated, and Cardiovascular Effects of Methamphetamine.
    Marks KR; Lile JA; Stoops WW; Glaser PE; Hays LR; Rush CR
    J Clin Psychopharmacol; 2016 Jun; 36(3):213-21. PubMed ID: 27043121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
    Greenway FL; Dunayevich E; Tollefson G; Erickson J; Guttadauria M; Fujioka K; Cowley MA;
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4898-906. PubMed ID: 19846734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.
    Anthenelli RM; Benowitz NL; West R; St Aubin L; McRae T; Lawrence D; Ascher J; Russ C; Krishen A; Evins AE
    Lancet; 2016 Jun; 387(10037):2507-20. PubMed ID: 27116918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.